These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 20807192

  • 1. Targeting interleukin (IL) 5 for asthma and hypereosinophilic diseases.
    Stein ML, Munitz A.
    Recent Pat Inflamm Allergy Drug Discov; 2010 Nov; 4(3):201-9. PubMed ID: 20807192
    [Abstract] [Full Text] [Related]

  • 2. Therapeutic strategies for harnessing human eosinophils in allergic inflammation, hypereosinophilic disorders, and cancer.
    Amini-Vaughan ZJ, Martinez-Moczygemba M, Huston DP.
    Curr Allergy Asthma Rep; 2012 Oct; 12(5):402-12. PubMed ID: 22875242
    [Abstract] [Full Text] [Related]

  • 3. Mepolizumab in eosinophilic disorders.
    Abonia JP, Putnam PE.
    Expert Rev Clin Immunol; 2011 Jul; 7(4):411-7. PubMed ID: 21790283
    [Abstract] [Full Text] [Related]

  • 4. Anti-interleukin-5 antibody therapy in eosinophilic diseases.
    Simon D, Braathen LR, Simon HU.
    Pathobiology; 2005 Jul; 72(6):287-92. PubMed ID: 16582580
    [Abstract] [Full Text] [Related]

  • 5. [Anti-interleukin-5 therapy for eosinophilic diseases].
    Simon D, Braathen LR, Simon HU.
    Hautarzt; 2007 Feb; 58(2):122, 124-7. PubMed ID: 17221241
    [Abstract] [Full Text] [Related]

  • 6. Changing roles of eosinophils in health and disease.
    Furuta GT, Atkins FD, Lee NA, Lee JJ.
    Ann Allergy Asthma Immunol; 2014 Jul; 113(1):3-8. PubMed ID: 24795292
    [Abstract] [Full Text] [Related]

  • 7. A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma.
    Busse WW, Ring J, Huss-Marp J, Kahn JE.
    J Allergy Clin Immunol; 2010 Apr; 125(4):803-13. PubMed ID: 20371394
    [Abstract] [Full Text] [Related]

  • 8. Anti-interleukin-5 therapy for asthma and hypereosinophilic syndrome.
    Kay AB, Klion AD.
    Immunol Allergy Clin North Am; 2004 Nov; 24(4):645-66, vii. PubMed ID: 15474864
    [Abstract] [Full Text] [Related]

  • 9. Eosinophils and interleukin-5: the debate continues.
    Kay AB, Menzies-Gow A.
    Am J Respir Crit Care Med; 2003 Jun 15; 167(12):1586-7. PubMed ID: 12796050
    [No Abstract] [Full Text] [Related]

  • 10. Antagonism of eosinophil accumulation in asthma.
    Walsh GM.
    Recent Pat Inflamm Allergy Drug Discov; 2010 Nov 15; 4(3):210-3. PubMed ID: 20804449
    [Abstract] [Full Text] [Related]

  • 11. Mepolizumab and eosinophil-mediated disease.
    Walsh GM.
    Curr Med Chem; 2009 Nov 15; 16(36):4774-8. PubMed ID: 19929788
    [Abstract] [Full Text] [Related]

  • 12. Anti-IL-5 and IL-5Ra: Efficacy and Safety of New Therapeutic Strategies in Severe Uncontrolled Asthma.
    Bagnasco D, Caminati M, Ferrando M, Aloè T, Testino E, Canonica GW, Passalacqua G.
    Biomed Res Int; 2018 Nov 15; 2018():5698212. PubMed ID: 30519580
    [Abstract] [Full Text] [Related]

  • 13. Interleukin-4/interleukin-13 versus interleukin-5: a comparison of molecular targets in biologic therapy for the treatment of severe asthma.
    Wu AY, Sur S, Grant JA, Tripple JW.
    Curr Opin Allergy Clin Immunol; 2019 Feb 15; 19(1):30-37. PubMed ID: 30407206
    [Abstract] [Full Text] [Related]

  • 14. Targeting eosinophil biology in asthma therapy.
    Wegmann M.
    Am J Respir Cell Mol Biol; 2011 Oct 15; 45(4):667-74. PubMed ID: 21474432
    [Abstract] [Full Text] [Related]

  • 15. Anti-interleukin-5 antibody therapy in asthma and allergies.
    Corren J.
    Curr Opin Allergy Clin Immunol; 2011 Dec 15; 11(6):565-70. PubMed ID: 21971335
    [Abstract] [Full Text] [Related]

  • 16. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes.
    Garrett JK, Jameson SC, Thomson B, Collins MH, Wagoner LE, Freese DK, Beck LA, Boyce JA, Filipovich AH, Villanueva JM, Sutton SA, Assa'ad AH, Rothenberg ME.
    J Allergy Clin Immunol; 2004 Jan 15; 113(1):115-9. PubMed ID: 14699394
    [Abstract] [Full Text] [Related]

  • 17. Eosinophil apoptosis as a therapeutic target in allergic asthma.
    Ilmarinen P, Kankaanranta H.
    Basic Clin Pharmacol Toxicol; 2014 Jan 15; 114(1):109-17. PubMed ID: 24148899
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma.
    Matera MG, Rogliani P, Calzetta L, Cazzola M.
    Expert Opin Drug Metab Toxicol; 2018 Feb 15; 14(2):239-245. PubMed ID: 29268638
    [Abstract] [Full Text] [Related]

  • 19. Allergic diseases: From bench to clinic - Contribution of the discovery of interleukin-5.
    Yanagibashi T, Satoh M, Nagai Y, Koike M, Takatsu K.
    Cytokine; 2017 Oct 15; 98():59-70. PubMed ID: 28863833
    [Abstract] [Full Text] [Related]

  • 20. Comparison of IL-33 and IL-5 family mediated activation of human eosinophils.
    Angulo EL, McKernan EM, Fichtinger PS, Mathur SK.
    PLoS One; 2019 Oct 15; 14(9):e0217807. PubMed ID: 31490928
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.